Biotech investor Bob Nelsen on AstraZeneca and his plan to revolutionize pharma
Audio is streamed directly from the publisher (chtbl.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
AstraZeneca and the University of Oxford today reported promising efficacy data for their COVID-19 vaccine, which has less stringent storage requirements than the Pfizer and Moderna vaccines and which may be distributed earlier in developing countries. Dan digs into the state of vaccine and therapeutics manufacturing with Bob Nelsen, a successful biotech investor who today launched Resilience, a giant new pharma production platform that he believes will prepare America for its next major health challenges.
Plus, Axios health care editor Sam Baker joins to discuss AstraZeneca’s interim analysis.